UBS analyst Eliana Merle raised the firm’s price target on Rapt Therapeutics (RAPT) to $9 from $8 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- Promising Potential of RAPT Therapeutics’ RPT904 Drives Buy Rating
- Rapt Therapeutics price target lowered to $38 from $51 at Wells Fargo
- RAPT Therapeutics: Anticipated Growth Driven by Strategic Partnerships and Promising Clinical Developments
- Rapt Therapeutics’ Reverse Stock Split: Potential Pitfalls and Market Challenges
- RAPT Therapeutics Reports Q2 2025 Financial Results